Le Lézard6d
Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Non-Muscle Invasive Bladder Cancer (SURF302)
Tyra Biosciences, Inc. , a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) ...
Toronto Life6d
Moss Park Consumption Treatment Services
The heads of Kensington Market Overdose Prevention Services say their centre has saved thousands of lives. Now, they worry ...